Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients With Pancreatic Cancer After Curative Resection

NCT02023021 is registered in ClinicalTrials.gov with Xian-Jun Yu as lead sponsor.

NCT NCT02023021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02023021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients With Pancreatic Cancer After Curative Resection
Lead sponsor
Xian-Jun Yu
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2014
Completion date
January 31, 2019
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage ia pancreatic adenocarcinoma, stage ib pancreatic adenocarcinoma, stage iia pancreatic adenocarcinoma, stage iib pancreatic adenocarcinoma